Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients

British Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2002, Pages 508-518

  Danesi, Romano ^a   Innocenti, Federico ^a   Fogli, Stefano ^a   Gennari, Alessandra ^b   Baldini, Editta ^b   Di Paolo, Antonello ^a   Salvadori, Barbara ^b   Bocci, Guido ^a   Conte, Pier Franco ^b   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Drug interaction; Epirubicin; Metabolism; Paclitaxel; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CREMOPHOR; EPIRUBICIN; EPIRUBICINOL; PACLITAXEL; 4' DEOXYDOXORUBICINOL; 4'-DEOXYDOXORUBICINOL; ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG DERIVATIVE; GLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; BONE MARROW TOXICITY; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG INFUSION; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; HUMAN; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG INTERACTION; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EPIRUBICIN; FEMALE; GLYCEROL; HUMAN; IN VITRO; INFUSIONS, INTRAVENOUS; MIDDLE AGE; PACLITAXEL; SUPPORT, NON-U.S. GOV'T; HUMANS; MIDDLE AGED;

EID: 0035999644     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01579.x     Document Type: Article

References (36)

1. Taxanes in the treatment of breast cancer: A prodigy comes of age
2. Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer
3. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
4. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
5. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
6. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
7. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion
8. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer
9. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer
10. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors
11. Structure and tissue-specific expression of the aldo-keto reductase superfamily
12. Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines
13. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
14. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer
15. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma
16. MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring
17. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic-pharmacodynamic relationships in humans
18. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
19. The taxoids. Comparative clinical pharmacology and therapeutic potential
20. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
21. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
22. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity
23. Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer
24. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer
25. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
26. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells
27. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
28. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
29. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo
30. Paclitaxel induces significant changes in epidoxorubicin distribution in mice
31. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart
32. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer
33. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity
34. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines